ReviewGels (Basel, Switzerland)2025
Novel Approaches for the 3D Printing of Collagen-Sourced Biomaterials Against Infectious and Cardiovascular Diseases.
Review in Gels (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Advances in 3D Bioprinting: Materials, Processes, and Emerging Applications.Micromachines · 2026Review
- Collagen Type I as a Biological Barrier Interface in Biomimetic Microfluidic Devices: Properties, Applications, and Challenges.Biomimetics (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Collagen is a versatile material, and collagen in the human body strengthens the muscles and related organs, allowing good substances to be absorbed into the bloodstream while preventing the absorption of toxic substances. Thus, collagen has been broadly applied in regenerative medicine and tissue engineering. A comprehensive framework for various collagen products has been created by integrating collagen resources with additive components. The application of 3D-bioprinting technologies for designing physiological models further allows for the introduction of enhanced preclinical testing tools that can contribute to successful elucidation of the mechanisms behind host-pathogen interactions, and subsequent prevention and treatment of various diseases. In this review, novel strategies for the 3D-printing production of collagen-sourced biomedical devices, as well as diverse applications customized with advanced artificial intelligence (AI) technologies, were thoroughly examined. Ongoing challenges, including the inherent limitations in the mechanical weakness of collagen-based bioinks, such as printability and stability, along with cell viability and bioavailability, and advanced strategies addressing those challenges, were also reviewed. An integration of 3D printing with collagen as a bioink is enormously efficient in biomedical applications, demonstrating its great potential for clinical translation against infectious diseases, including cardiovascular diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.